Rubedo Life Sciences, a biopharmaceutical company focused on developing therapies for age-related diseases, has closed a $40 million Series A financing round. The funding was led by Khosla Ventures and Ahren Innovation Capital.
Rubedo’s approach targets senescent cells which can accumulate over time and cause chronic inflammation, leading to fibrosis and tissue degeneration. The company’s drug discovery platform, Alembic, identifies pathologic cells like these to develop targeted therapeutics that can prevent or reverse the resulting age-related diseases.
The company plans to use the money to advance its lead candidate into phase 1 studies for chronic atopic dermatitis and chronic psoriasis. Rubedo is also developing therapies for pulmonary diseases such as idiopathic pulmonary fibrosis.
